Back

PCSK9 inhibition and cardiovascular outcomes by heart failure status: a pooled analysis of SPIRE-1 and SPIRE-2

10 May 2026 (16:30 - 17:00)
Organised by: Logo
Congress Presentation Part of: Integrated and multidisciplinary care strategies to prevent remodelling in heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Amir Razaghizad

Montreal (Canada)

4 More presentations in this session

Presentation thumbnail
Impact of early initiation of sodium-glucose cotransporter 2 inhibitors on cardiac remodeling in patients with acute myocardial infarction: a meta-analysis and trial sequential analysis of controlled
Associate Professor D. D'Amario (Novara, IT)
Abstract Slides Video
Presentation thumbnail
Real-world outcomes and predictors of LV reverse remodelling after successful CTO PCI in HFrEF: insights from a multicentre registry
Assistant Professor J. Park (Busan, KR)
Abstract Slides Video
Presentation thumbnail
Impact of heart failure etiology after CRT upgrade
Associate Professor A. Kosztin (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of beta-blocker therapy after myocardial infarction in patients with preserved or mildly reduced ejection fraction
Doctor B. Resende (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Integrated and multidisciplinary care strategies to prevent remodelling in heart failure

The Event

Event poster

Heart Failure 2026

10 May 2026 16:30 CET
You may be interested in
thumbnail
Congress Session
Advances in heart failure detection and therapy
thumbnail
Congress Session
Late breaking clinical trials: drugs and devices
thumbnail
Congress Presentation
Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources